DURECT Announces REMOXY New Drug Application Accepted by the FDA

DURECT Corporation DRRX today reported that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for REMOXY by King Pharmaceuticals, Inc. KG and the PDUFA goal date is June 23, 2011. REMOXY, based on DURECT's ORADUR® technology, is an investigational drug that is a unique, controlled release formulation of oxycodone for moderate-to-severe chronic pain designed to reduce potential risks of unintended use. Approximately 50 million Americans suffer from persistent pain each year, according to the American Pain Foundation.